Neil O'Brien

6PUBLICATIONS
59CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 05, 2026
Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer.

|Oct 03, 2023
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.

Neil A O'Brien, Martina S J McDermott, Jun Zhang

|Apr 11, 2023
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.

Rohan Diwanji, Neil A O'Brien, Jiyoung E Choi

|Mar 08, 2023
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.

Martina S J McDermott, Neil A O'Brien, Benjamin Hoffstrom

|Sep 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.

Zev A Wainberg, Arun S Singh, Gottfried E Konecny

|Aug 16, 2020
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

Neil A O'Brien, Martina S J McDermott, Dylan Conklin

Pageof 1

Frequent Collaborators

4 joint publications

John Glaspy

4 joint publications

Dennis J Slamon

3 joint publications

Martina S J McDermott

3 joint publications

Benjamin Hoffstrom